Get started

Stockpicks

A Buy and Forget? YJI decided to just get Yunjji at a 22% price premium, for various reasons: 1) They have a large membership, and are relatively small for a trending space for investors. 2) Look at the $BABA and $JMIA play. 3) Market cap is only $595.55M, which is relatively small. Anyways, I took a small position in it as I'm cautious, but definitely on the watchlist. That said, do your own due diligence and invest at your own risk. Everything I say is on an opinion based basis.
NASDAQ:YJLong
by gamer456148
Wait Until the $15+ Wave: Reiterating LongAgain, I think this is one of the more decent speculative plays or dip opportunities for a swing out there. Shorts are soon going to need to likely cover, you have an RSI less than 30, and people are overreacting to the clinical data and news headlines. The support level just needs to pickup for a really good squeeze. PR could come like a hammer for overly anxious bears. That said, please invest at your own risk and do your own due diligence. Everything I say is on an opinion based basis.
NASDAQ:VXRTLong
by gamer456148
GEO Technical Analysis 🧙The GEO Group Inc. is a real estate investment trust specializing in detention facilities and community-reentry centers. The company leases and oversees secure detention centers, rehabilitation and reentry facilities, and service centers for troubled youth. The GEO Group also provides counseling, education, drug abuse treatment, technology-based supervision programs, and detainee transportation. The majority of revenue comes from leasing and managing U.S. corrections & detention facilities. The GEO Group also operates in Australia, South Africa, and the United Kingdom. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:GEOLong
by trading_as_bus
10
MAC Technical Analysis 🧙The Macerich Company is an S&P 500 company that invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 19 regional malls in its unconsolidated portfolio along with six power centers and six other real estate assets. The company's total portfolio has 50.6 million square feet gross leasable area and averaged $801 sales per square foot for the past 12 months, with the consolidated portfolio averaging $646 sales per square foot and the unconsolidated portfolio averaging $998 sales per square foot. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:MACLong
by trading_as_bus
1
VYGR Technical Analysis 🧙Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease, VY-HTT01 for Huntington's Disease. Voyager's sole source of revenue is generated through its collaboration with a company called Genzyme. Genzyme funds the collaboration for the multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia, and Huntington's disease, as well as other CNS disorders. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:VYGRLong
by trading_as_bus
2
$BCRX PT 23 and higher (fm @Snake Doc)BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
NASDAQ:BCRXLong
by BADQOMOCAWGOWLD
1
$ATHE is $SAVA sympathy play...Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
NASDAQ:ATHE
by BADQOMOCAWGOWLD
My Weekly Opportunity WatchlistENVB and AEZS has positive sentiment to pickup, and some people are turning to AEZS out of excitement of a potential VXRT-like rise. DRCB is a decent entry for a long hold or a short term swing. WTI looks like it is going to go up w/ increased demand in gas and was previously oversold prior to picking up support levels. JDST will grow off of precious metals sentiment trending. Everything I'm saying is on an opinion based basis. Please invest at your own risk and do your own due diligence.
NASDAQ:ENVBLong
by gamer456148
Acquires Exclusive Rights to Rare Earth Element InnovationsAmerican Resources Corporation Acquires Exclusive Rights to Purdue University's Rare Earth Element Innovations, Critical for Clean Energy Technologies. An environmentally safer method of rare earth and other critical material separation and purification using ligand-assisted chromatography for coal, coal byproducts, recycled permanent magnets and Lithium Ion batteries. Announced that, with the addition of Hasler Ventures LLC, the Company has licensed ligand assisted displacement ("LAD") chromatography patents and knowhow to further expanded its capability in environmentally friendly separation and purification of rare earth elements. These exclusive patents and technologies, developed at Purdue University, are specific to the processing of separated and pure rare earth metals and critical elements from coal byproducts, recycled permanent magnets and lithium-ion batteries. Rare earth elements (REEs) include the 15 elements in the lanthanide series plus scandium (Sc) and yttrium (Y). They are essential ingredients for magnets, metal alloys, polishing powders, catalysts, ceramics, and phosphors, which are important for high-technology and clean energy applications. The global REE market is estimated at approximately $4 billion dollars and growing at 8% per year. finance.yahoo.com
NASDAQ:AREC
by AlenCiken
2